Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)
about
Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritisInterleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
P2860
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Updated consensus statement on ...... heumatic diseases (April 2001)
@ast
Updated consensus statement on ...... heumatic diseases (April 2001)
@en
Updated consensus statement on ...... s and other rheumatic diseases
@nl
type
label
Updated consensus statement on ...... heumatic diseases (April 2001)
@ast
Updated consensus statement on ...... heumatic diseases (April 2001)
@en
Updated consensus statement on ...... s and other rheumatic diseases
@nl
prefLabel
Updated consensus statement on ...... heumatic diseases (April 2001)
@ast
Updated consensus statement on ...... heumatic diseases (April 2001)
@en
Updated consensus statement on ...... s and other rheumatic diseases
@nl
P2093
P2860
P1476
Updated consensus statement on ...... heumatic diseases (April 2001)
@en
P2093
Breedveld FC
Crofford LJ
Kavanaugh A
Keystone EC
P2860
P304
P407
P478
60 Suppl 3
P577
2001-11-01T00:00:00Z